PLERIXAFOR

Plerixafor mobilizes hematopoietic stem cells by antagonizing CXCR4, used before autologous transplantation. Side effects include diarrhea, injection-site pain, leukocytosis, and splenic enlargement. Only GMP materials will be supplied, logistics all according to GDP.

Category:

Product Description


Mechanism of Action

PLERIXAFOR demonstrates a highdimensional biochemical activity framework integrating catalyticdomain modulation, multiaxis signalling interference, mitochondrialnetwork recalibration, redoxequilibrium restructuring, ionflux redistribution, membranepotential modulation, cytoskeletalarchitecture remodelling and transcriptionfactor circuit reprogramming. The compounds molecular topology supports interaction with catalytic residues, allosteric microdomains, transmembrane helices, nucleotidebinding pockets, redoxbuffer matrices and polymeric scaffolding complexesenabling influence across metabolic, genomic, structural and electrophysiological systems.

PLERIXAFOR may alter phosphorylationflow geometry across ERK, MAPK, JNK, p38 and PI3KAKT axes; reconfigure Gprotein signalstate logic; redistribute Ca²⁺ microdomains; adjust IP/DAG signalling topology; and recalibrate cAMPPKA amplitude. Mitochondrial effects include ETCcomplex rebalancing, ATP/ADP flux modulation, ROSthreshold displacement, membranepotential polarity shifting, and ERmitochondria stresssignal crosstalk integration.

HighPrecision

  • Kinomescale interference mapping & catalyticcascade modelling
  • Highresolution molecular docking & conformationaltransition prediction
  • UPR/ERstress, mitophagy & autophagicflux regulatory modelling
  • Multiomics network reconstruction: RNAseq, metabolomics, proteomics, phosphoproteomics
  • Cytoskeletal tensionmapping & polymerturnover analytics
  • Advanced cellfate pathway modelling (apoptosis, necroptosis, ferroptosis, parthanatos)
  • AIdriven SAR/QSAR predictive compoundperformance optimisation

Toxicodynamics & Hazard Spectrum

  • Rapid ROS escalation & antioxidantbuffer collapse
  • Mitochondrial fragmentation or ETCaxis suppression
  • Severe Na⁺/K⁺/Ca²⁺ ionic-flux destabilisation
  • Cytoskeletal depolymerisation & membrane-integrity loss
  • Inflammatory hyperactivation (NF-κB, STAT, IRF signalling clusters)
  • Activation of multiaxis programmed-cell-death pathways
  • Epigenetic drift including methylation/acetylation instability

For expert not intended for biological or therapeutic exposure.

Only GMP materials will be supplied, logistics all according to GDP.

Datasheet


Molecular Formula

C28H54N8

Molecular Weight

502.8 g/mol

CAS Number

110078-46-1

Storage Condition

Store in a cool, dry place. Keep container tightly closed. Protect from moisture and light.

Solubility

Slightly soluble

Purity

Purity information is available upon request (COA).

Synonym

Plerixafor; 110078-46-1; Mozobil; AMD3100; Amd 3100

IUPAC/Chemical Name

1-[[4-(1,4,8,11-tetrazacyclotetradec-1-ylmethyl)phenyl]methyl]-1,4,8,11-tetrazacyclotetradecane

InChl Key

YIQPUIGJQJDJOS-UHFFFAOYSA-N

InChl Code

InChI=1S/C28H54N8/c1-9-29-15-17-31-13-3-21-35(23-19-33-11-1)25-27-5-7-28(8-6-27)26-36-22-4-14-32-18-16-30-10-2-12-34-20-24-36/h5-8,29-34H,1-4,9-26H2

References

https://pubchem.ncbi.nlm.nih.gov/compound/65015;

3D Conformer.

(Click, turn or enlarge)

Download our GMP API Product List.

MedicaPharma is an EU-based supplier of GMP-certified APIs that serves leading healthcare institutions and research organizations.
Click here to download our full API product list.

Download